Eiger BioPharmaceuticals, Inc. (EIGRQ)

Eiger BioPharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	25.44	25.44	25.8	22.22	28.86	39.37
Short-Term Investments	0	0	73.15	66.59	99.98	55.62
Cash & Cash Equivalents	25.44	25.44	98.95	88.82	128.84	94.99
Cash Growth	-74.29%	-74.29%	11.41%	-31.07%	35.63%	-5.34%
Receivables	1.68	1.68	1.75	2.58	0	0
Inventory	1.56	1.56	2.85	2.61	0.09	0
Other Current Assets	9.16	9.16	13.99	9.36	8.87	5.39
Total Current Assets	37.84	37.84	117.54	103.36	137.81	100.38
Property, Plant & Equipment	0.63	0.63	0.7	1.27	1.89	2.24
Long-Term Investments	0	0	0	17.26	0	0
Other Long-Term Assets	0.36	0.36	1.91	4.51	3.9	2.51
Total Long-Term Assets	0.99	0.99	2.6	23.04	5.79	4.76
Total Assets	38.83	38.83	120.14	126.4	143.59	105.14
Accounts Payable	2.12	2.12	8.98	7.77	4.64	6.41
Current Debt	41.2	41.2	0.49	8.44	0.58	0.53
Other Current Liabilities	9.97	9.97	15.66	13.7	11.41	10
Total Current Liabilities	53.28	53.28	25.12	29.9	16.63	16.95
Long-Term Debt	0	0	39.71	24.1	31.93	31.71
Total Long-Term Liabilities	0	0	39.71	24.1	31.93	31.71
Total Liabilities	53.28	53.28	64.83	54	48.56	48.66
Total Debt	41.2	41.2	40.2	32.54	32.51	32.24
Debt Growth	2.50%	2.50%	23.54%	0.08%	0.84%	25.85%
Retained Earnings	-512.16	-512.16	-437.19	-340.42	-306.5	-241.45
Comprehensive Income	-0.17	-0.17	-0.3	-0.15	-0.01	0.04
Shareholders' Equity	-14.46	-14.46	55.31	72.4	95.04	56.48
Net Cash / Debt	-15.76	-15.76	58.75	56.28	96.33	62.75
Net Cash / Debt Growth	-	-	4.39%	-41.58%	53.51%	-16.03%
Net Cash Per Share	-10.68	-10.68	42.34	49.74	102.68	82.62
Working Capital	-15.45	-15.45	92.41	73.46	121.18	83.44
Book Value Per Share	-9.79	-9.79	39.86	63.99	101.30	74.36

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).